| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Ceftaroline |
| Brand | Zinforo® |
| Indication | For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP). |
| Assessment Process | |
| Rapid review commissioned | 08/10/2012 |
| Rapid review completed | 12/10/2012 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that ceftaroline be considered for reimbursement |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
